The Food and Drug Administration told Amazon in an October 1, 2026, warning letter that nine herpes-related products it had bought on Amazon.com in July are unapproved new drugs, among them FemiClear, HerpCare Ointment and Herstat GST. The agency said Amazon distributed the products to U.S. consumers through Fulfillment by Amazon, the program that stores and ships goods for third-party sellers.
The tech news worth your time: 400,000+ professionals from Google, Apple and OpenAI read Techpresso, a daily email with the most interesting tech news and insights.
We may earn a commission if you sign up.
The letter was addressed to Amazon chief executive Andy Jassy and signed by Tina Smith, director of the Office of Unapproved Drugs and Labeling Compliance in the agency’s drug center. It rests on a plain premise: the FDA has not approved any over-the-counter drug for treating, curing, mitigating or preventing sexually transmitted infections.
The nine products and the claims on their labels
The warning letter, reference number 736006, quotes the labeling of each product. FemiClear is described as a “fast-acting ointment for recurring outbreak symptoms” under the heading genital herpes symptoms. HerpCare Ointment promises “fast-acting genital herpes symptom relief” and says it “soothes and calms genital sores.” HerpCare Spray is sold for herpes symptoms and for soothing irritation, burning and itching.
The rest of the list reads the same way. HClear for him cites a figure that more than 90 percent of users reported less severe outbreaks. Herstat GST is billed as a genital sore treatment, a product called Genital Herpes Ointment promises fast-acting relief, and RoyceDerm Herpes Relief Cream says it “fights outbreaks” and “reduces recurrence.” Terragen HG Formula is labeled for swelling and pain from genital sores, and a Genital Herpes Intimate Wash is formulated for herpes relief with antiviral and pain relief claims.
Intended use and the unapproved new drug rules
The legal logic turns on what a product claims to do. Under the FDA’s regulation on intended use in 21 CFR 201.128, the objective intent of the people responsible for labeling can be shown by label claims, advertising and the circumstances of distribution. A cream that promises to fight herpes outbreaks is, by that standard, a drug, whatever the package calls it.
Once a product is a drug and is not generally recognized as safe and effective for the use on its label, it is a new drug. The statute, section 505(a) of the Federal Food, Drug, and Cosmetic Act, bars anyone from sending a new drug into interstate commerce unless an approved application is in effect, as 21 U.S.C. 355 spells out. The letter also cites section 301(d), which prohibits introducing such drugs into commerce, and says Herstat GST has no basis for lawful marketing without an approved application.
Homeopathic labels do not change the analysis
Several of the products present as homeopathic, and the letter anticipates that defense. Terragen HG Formula is homeopathic, the FDA says, but remains subject to the same drug requirements. For FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray and Genital Herpes Ointment, the agency says they fall outside its December 2022 homeopathic guidance because they contain lemongrass, an ingredient not listed in the Homeopathic Pharmacopeia of the United States.
Even inside that guidance, the FDA says, the products would land in a higher-risk category it intends to prioritize. The homeopathic drug guidance lists those categories, including products meant to prevent or treat serious or life-threatening diseases, because users may delay or skip effective approved treatment. It also states that any homeopathic product marketed illegally is subject to enforcement action at any time.
Herstat GST is handled differently. The FDA says its intended use, relief of genital sores, goes beyond what the OTC monograph for external analgesics permits, which covers pain, itching and minor skin irritation. That gap matters because a monograph is one route by which an over-the-counter drug can be sold without its own approved application, and the letter says a claim to treat genital sores falls outside it. Even a product that borrows the language of an accepted pain reliever, in other words, cannot stretch it to cover a sexually transmitted infection.
What Amazon must do and what a warning letter means
The letter asks Amazon to address the violations promptly and to send a written response to [email protected] within 15 business days of receipt, with reference number 736006 in the subject line. The response should describe the corrective steps taken, explain how recurrence will be prevented, and include supporting documentation or any evidence that the products comply with the law.
The consequences for ignoring it are laid out too. Failure to adequately address the violations may lead to regulatory or legal action without further notice, including seizure and injunction. The FDA’s own warning letters listing cautions that later contact between the agency and a recipient can change the regulatory status of the issues in a posted letter, so the letter is a snapshot, not a final ruling. Posted to the FDA’s site on October 6, it does not by itself say any person was harmed by the products.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
The tech news worth your time: Subscribe to Techpresso →
We may earn a commission if you sign up.
More from Morning Overview
- Two passengers died at an Ohio toll plaza, and the NTSB now wants the cash lanes shut
- Long use of a common prostate pill is tied to a higher chance of glaucoma
- Ford is recalling 223,472 F-150 pickups because the fuel tank can leak or detach
- Hybrids have 15% fewer problems than gas cars, while EVs and plug-in hybrids have about 80% more, Consumer Reports finds
